129 related articles for article (PubMed ID: 12108915)
1. Reporting of adverse event data in hematopoietic stem cell transplantation clinical trials involving investigational new drugs or devices: a report from the William Guy Forbeck Foundation 2001 focus meeting on clinical trials in hematopoietic stem cell transplantation.
Martin PJ; Antin JH; Weisdorf DJ; Paton V; Horowitz MM
Biol Blood Marrow Transplant; 2002; 8(6):295-302. PubMed ID: 12108915
[TBL] [Abstract][Full Text] [Related]
2. Clinical research: the best or worst of times?
Ferrara JL; Wingard JR
Biol Blood Marrow Transplant; 2002; 8(6):293-4. PubMed ID: 12108914
[No Abstract] [Full Text] [Related]
3. [The role of the Danish Medical Products Agency in clinical trials].
Simonsen AC
Ugeskr Laeger; 2003 Apr; 165(16):1653-6. PubMed ID: 12756821
[TBL] [Abstract][Full Text] [Related]
4. Clinical trials in stem cell transplantation: guidelines for scientific and ethical review.
Lo B; Kriegstein A; Grady D
Clin Trials; 2008; 5(5):517-22. PubMed ID: 18827044
[TBL] [Abstract][Full Text] [Related]
5. Conducting clinical trials in Singapore.
Woo KT
Singapore Med J; 1999 Apr; 40(4):310-3. PubMed ID: 10487091
[TBL] [Abstract][Full Text] [Related]
6. Autologous hematopoietic stem cell transplantation for pediatric solid tumors.
Hale GA
Expert Rev Anticancer Ther; 2005 Oct; 5(5):835-46. PubMed ID: 16221053
[TBL] [Abstract][Full Text] [Related]
7. The impact of escalating regulatory requirements on the conduct of clinical research.
Gordon BG; Kessinger A; Mann SL; Prentice ED
Cytotherapy; 2003; 5(4):309-13. PubMed ID: 12944237
[TBL] [Abstract][Full Text] [Related]
8. Establishing pan-European clinical trials: regulatory compliance and other practical considerations.
Grienenberger A
J Biolaw Bus; 2004; 7(4):58-63. PubMed ID: 15675097
[TBL] [Abstract][Full Text] [Related]
9. Cell-based interventions for neurologic conditions: ethical challenges for early human trials.
Mathews DJ; Sugarman J; Bok H; Blass DM; Coyle JT; Duggan P; Finkel J; Greely HT; Hillis A; Hoke A; Johnson R; Johnston M; Kahn J; Kerr D; Kurtzberg J; Liao SM; McDonald JW; McKhann G; Nelson KB; Rao M; Regenberg A; Siegel AW; Smith K; Solter D; Song H; Vescovi A; Young W; Gearhart JD; Faden R
Neurology; 2008 Jul; 71(4):288-93. PubMed ID: 18463365
[TBL] [Abstract][Full Text] [Related]
10. Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation.
Tichelli A; Passweg J; Wójcik D; Rovó A; Harousseau JL; Masszi T; Zander A; Békássy A; Crawley C; Arat M; Sica S; Lutz P; Socié G;
Haematologica; 2008 Aug; 93(8):1203-10. PubMed ID: 18556401
[TBL] [Abstract][Full Text] [Related]
11. Allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning in acute lymphoblastic leukemia: a feasibility study.
Martino R; Giralt S; Caballero MD; Mackinnon S; Corradini P; Fernández-Avilés F; San Miguel J; Sierra J
Haematologica; 2003 May; 88(5):555-60. PubMed ID: 12745275
[TBL] [Abstract][Full Text] [Related]
12. Ocular findings after allogeneic hematopoietic stem cell transplantation.
Tabbara KF; Al-Ghamdi A; Al-Mohareb F; Ayas M; Chaudhri N; Al-Sharif F; Al-Zahrani H; Mohammed SY; Nassar A; Aljurf M
Ophthalmology; 2009 Sep; 116(9):1624-9. PubMed ID: 19729097
[TBL] [Abstract][Full Text] [Related]
13. Randomized clinical trials for hematopoietic stem cell transplantation: lessons to be learned from the European experience.
Kuthiala SS; Lyman GH; Ballester OF
Bone Marrow Transplant; 2006 Jan; 37(2):219-21. PubMed ID: 16299544
[TBL] [Abstract][Full Text] [Related]
14. [The inspection by the Danish Medical Products Agency of drug clinical trials].
Jacobsen E; Stilbo I
Ugeskr Laeger; 2003 Apr; 165(16):1656-8. PubMed ID: 12756822
[TBL] [Abstract][Full Text] [Related]
15. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
16. Cytomegalovirus prophylaxis and treatment after hematopoietic stem cell transplantation in Canada: a description of current practices and comparison with Centers for Disease Control/Infectious Diseases Society of America/American Society for Blood and Marrow Transplantation guideline recommendations.
Fraser GA; Walker II;
Biol Blood Marrow Transplant; 2004 May; 10(5):287-97. PubMed ID: 15111928
[TBL] [Abstract][Full Text] [Related]
17. Standardized assessment of adverse events in rheumatology clinical trials: summary of the OMERACT 7 drug safety module update.
Lassere MN; Johnson KR; Boers M; Carlton K; Day RO; de Wit M; Edwards IR; Fries JF; Furst DE; Kirwan JR; Tugwell PS; Woodworth TG; Brooks PM
J Rheumatol; 2005 Oct; 32(10):2037-41. PubMed ID: 16206366
[TBL] [Abstract][Full Text] [Related]
18. [The GCP directive--consequences for clinical drug research].
Gluud CN
Ugeskr Laeger; 2003 Apr; 165(16):1662-4. PubMed ID: 12756824
[TBL] [Abstract][Full Text] [Related]
19. Bronchiolitis obliterans following pediatric allogeneic hematopoietic stem cell transplantation.
Duncan CN; Buonanno MR; Barry EV; Myers K; Peritz D; Lehmann L
Bone Marrow Transplant; 2008 Jun; 41(11):971-5. PubMed ID: 18297116
[TBL] [Abstract][Full Text] [Related]
20. The EBMT activity survey 2006 on hematopoietic stem cell transplantation: focus on the use of cord blood products.
Gratwohl A; Baldomero H; Frauendorfer K; Rocha V; Apperley J; Niederwieser D; ;
Bone Marrow Transplant; 2008 Apr; 41(8):687-705. PubMed ID: 18084334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
